Sudip Bandopadhyay, Market Expert told CNBC-TV18, "We have been bullish on Sun Pharma. We strongly believe that the negative news flow pertaining to the company is a matter of the past. Integration issues which they were facing post the Ranbaxy acquisition has to a great extent been resolved. Things are moving in the right direction. They had some problem with US regulator, even that to a great extent is getting resolved.""We believe post the correction which the counter witnessed over the last few months, it is a great opportunity for long term investors to buy at current valuation with one year plus time horizon in mind," he said.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
